Monofer (Ferric Derisomaltose)

Ferric derisomaltose is a stable iron‑carbohydrate complex. After intravenous administration, the complex is taken up by reticulo‑endothelial cells, where it is broken down and releases bioavailable ferrous iron. This iron binds to transferrin, increasing circulating iron levels and supporting hemoglobin synthesis and cellular iron‑dependent processes.

The dose of Monofer is individualized. A prescriber determines the total iron requirement based on the patient’s hemoglobin, body weight, and degree of iron deficiency, and then calculates the appropriate infusion volume. Specific dosing regimens are not provided here and should follow the prescribing information.

Safety data for Monofer in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians must evaluate the clinical situation and discuss possible risks with the patient.

To order Monofer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Monofer (ferric derisomaltose) delivers a large iron dose in a single infusion, whereas agents like iron sucrose or ferric carboxymaltose may require multiple administrations. Monofer’s stable complex allows rapid repletion with a lower risk of free‑iron reactions, but choice of product depends on patient factors, dosing convenience, and clinician preference.

Monofer must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Before use, allow the product to reach room temperature if required by the preparation instructions.

Monofer is given as an intravenous infusion. The vial is diluted with the appropriate diluent according to the manufacturer’s instructions and infused over a period that may range from a few minutes to an hour, depending on the total dose and patient tolerance. Administration should be performed by qualified healthcare personnel.

The most serious adverse events include anaphylactic or severe allergic reactions, marked hypotension, and significant hypophosphatemia. Patients should be monitored during and after the infusion for signs of respiratory distress, sudden blood pressure changes, or electrolyte disturbances, and appropriate emergency measures should be readily available.

Monofer is contraindicated in individuals with known hypersensitivity to ferric derisomaltose or any component of the formulation, as well as in patients with iron overload disorders such as hemochromatosis. Caution is also advised for patients with active severe infections, uncontrolled hypertension, or those who are pregnant or breastfeeding unless the benefit outweighs the risk.